Phase 4 Haemophilia Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People who have severe haemophilia A, meaning their Factor VIII (a blood clotting protein) level is less than 1% of normal, based on their medical history
- People who are male and at least 12 years old
- People who have previously been treated with a Factor VIII product on at least 150 separate occasions
- People who have been on a regular preventative treatment programme using emicizumab for at least 1 month before a planned major surgery that will require Factor VIII treatment
- People (or their parent or legal guardian, if applicable) who are willing and able to provide written consent to participate, in line with local rules
Who may not be able to join:
- People who have a blood clotting disorder other than haemophilia A
- People who have ever developed antibodies (called inhibitors) that work against Factor VIII treatment, at a level of 0.6 Bethesda units or higher, based on their medical history
- People with severe liver or kidney disease, as shown by certain abnormal blood test results (confirm with trial site)
- People who have a known allergy or sensitivity to the study drug Nuwiq or any of its ingredients, including sucrose, sodium chloride, calcium chloride dihydrate, arginine hydrochloride, sodium citrate dihydrate, or poloxamer 188
- People who have already had surgery as part of this study
- People who are currently taking part in another clinical trial that involves a treatment intervention
- People who have received any experimental or investigational medication within the 30 days before their screening visit
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Shveta Gupta, MD, Arnold Palmer Hospital for Children
Phone: +41 554512141
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Overall haemostatic efficacy
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.